RAGE and HMGB1 Expression in Orbital Tissue Microenvironment in Graves' Ophthalmopathy

被引:4
作者
Lacheta, Dominika [1 ]
Poslednik, Krzysztof B. [2 ]
Czerwaty, Katarzyna [2 ]
Ludwig, Nils [3 ]
Molinska-Glura, Marta [4 ]
Kantor, Ireneusz [2 ]
Jablonska-Pawlak, Anna [5 ]
Miskiewicz, Piotr [6 ]
Gluszko, Alicja [1 ]
Stopa, Zygmunt [7 ]
Brzost, Jacek [8 ]
Szczepanski, Miroslaw J. [1 ,2 ]
机构
[1] Med Univ Warsaw, Dept Biochem, PL-02097 Warsaw, Poland
[2] Med Ctr Postgrad Educ, Dept Otolaryngol, PL-03242 Warsaw, Poland
[3] Univ Hosp Regensburg, Dept Oral & Maxillofacial Surg, D-93053 Regensburg, Germany
[4] Poznan Univ Life Sci, Dept Forest Technol, PL-60624 Poznan, Poland
[5] Med Univ Warsaw, Dept Ophthalmol, PL-02097 Warsaw, Poland
[6] Med Univ Warsaw, Dept Internal Med & Endocrinol, PL-02097 Warsaw, Poland
[7] Med Univ Warsaw, Dept Maxillofacial Surg, PL-02097 Warsaw, Poland
[8] Childrens Mem Hlth Inst, Dept Otolaryngol, PL-04730 Warsaw, Poland
关键词
GLYCATION END-PRODUCTS; RECEPTOR RAGE; PROTEIN; PATHOGENESIS; IMMUNE; RHINOSINUSITIS; INFLAMMATION; ORBITOPATHY; MANAGEMENT; ARTHRITIS;
D O I
10.1155/2021/8891324
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Graves' ophthalmopathy (GO) is a chronic autoimmune inflammatory disorder involving orbital tissues. A receptor for advanced glycation end products (RAGE) and its ligand high mobility group box 1 (HMGB1) protein trigger inflammation and cell proliferation and are involved in the pathogenesis of various chronic inflammatory diseases. This study was aimed to evaluate RAGE and HMGB1 expression in GO to determine its potential clinical significance. To the best of our knowledge, this is the first study showing RAGE and HMGB1 expression in orbital tissue using immunohistochemistry. Sections of orbital adipose tissue obtained from patients diagnosed with GO (23 patients; 36 orbits) and normal controls (NC) (15 patients; 15 orbits) were analyzed by immunohistochemistry for RAGE and HMGB1 expression. Expression profiles were then correlated with clinical data of the study group. RAGE and HMGB1 expression were elevated in GO patients in comparison with NC (p = 0.001 and p = 0.02, respectively). We observed a correlation between RAGE expression and occurrence of dysthyroid optic neuropathy (DON) (p = 0.05) and levels of TSH Receptor Antibodies (TRAb) (p = 0.01). Overexpression of RAGE and HMGB1 might be associated with GO pathogenesis. In addition, RAGE and HMGB1 proteins may be considered as promising therapeutic targets, but this requires further research.
引用
收藏
页数:7
相关论文
共 32 条
  • [1] HMGB1, a pro-inflammatory cytokine of clinical interest: introduction
    Andersson, UG
    Tracey, KJ
    [J]. JOURNAL OF INTERNAL MEDICINE, 2004, 255 (03) : 318 - 319
  • [2] The EUGOGO consensus statement on the management of graves' orbitopathy: Equally applicable to North American clinicians and patients
    Bahn, Rebecca
    [J]. THYROID, 2008, 18 (03) : 281 - 282
  • [3] MECHANISMS OF DISEASE Graves' Ophthalmopathy
    Bahn, Rebecca S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (08) : 726 - 738
  • [4] The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy
    Bartalena, Luigi
    Baldeschi, Lelio
    Boboridis, Kostas
    Eckstein, Anja
    Kahaly, George J.
    Marcocci, Claudio
    Perros, Petros
    Salvi, Mario
    Wiersinga, Wilmar M.
    [J]. EUROPEAN THYROID JOURNAL, 2016, 5 (01) : 9 - 26
  • [5] The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: A novel pathway for inflammatory cell recruitment
    Chavakis, T
    Bierhaus, A
    Al-Fakhri, N
    Schneider, D
    Witte, S
    Linn, T
    Nagashima, M
    Morser, J
    Arnold, B
    Preissner, KT
    Nawroth, PP
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (10) : 1507 - 1515
  • [6] Clinical Relevance of Thyroid-Stimulating Autoantibodies in Pediatric Graves' Disease-A Multicenter Study
    Diana, T.
    Brown, R. S.
    Bossowski, A.
    Segni, M.
    Niedziela, M.
    Koenig, J.
    Bossowska, A.
    Ziora, K.
    Hale, A.
    Smith, J.
    Pitz, S.
    Kanitz, M.
    Kahaly, G. J.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (05) : 1648 - 1655
  • [7] Expression of the Receptor for Advanced Glycation End Products, a Target for High Mobility Group Box 1 Protein, and its Role in Chronic Recalcitrant Rhinosinusitis with Nasal Polyps
    Dzaman, Karolina
    Szczepanski, Miroslaw J.
    Molinska-Glura, Marta
    Krzeski, Antoni
    Zagor, Mariola
    [J]. ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2015, 63 (03) : 223 - 230
  • [8] High motility group box 1 (HMGB1) protein and its receptor for advanced glycation end products (RAGE) expression in chronic rhinosinusitis without nasal polyps
    Dzaman, Karolina
    Zagor, Mariola
    Molinska-Glura, Marta
    Krzeski, Antoni
    [J]. FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, 2015, 53 (01) : 70 - 78
  • [9] Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy
    Gerding, MN
    van der Meer, JWC
    Broenink, M
    Bakker, O
    Wiersinga, WM
    Prummel, MF
    [J]. CLINICAL ENDOCRINOLOGY, 2000, 52 (03) : 267 - 271
  • [10] High-Mobility Group Box 1 Is Associated with the Inflammatory Pathogenesis of Graves' Orbitopathy
    Han, So Young
    Choi, Soo Hyun
    Shin, Jeon-Soo
    Lee, Eun Jig
    Han, Sueng-Han
    Yoon, Jin Sook
    [J]. THYROID, 2019, 29 (06) : 868 - 878